Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ultragenyx Pharmaceutical Inc. provides biotechnology services. The Company develops therapeutics and sialic acid for treating metabolic, body myopathy, glucuronidase, and rare genetic diseases. Ultragenyx Pharmaceutical conducts its business in the United States.
Website: ultragenyx.com



Growth: Good revenue growth rate 15.1%, there is slowdown compared to average historical growth rates 22.8%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -84.1%. On average the margin is decreasing steadily. Gross margin is high, +82.5%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.6 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -38.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 23.3% higher than minimum and 59.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.5x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.3 mln (-0.013% of cap.)

Key Financials (Download financials)

Ticker: RARE
Share price, USD:  (0.0%)24.31
year average price 33.21  


year start price 45.35 2025-02-08

max close price 45.35 2025-02-08

min close price 19.72 2025-12-29

current price 24.31 2026-02-07
Common stocks: 70 152 192

Dividend Yield:  0.0%
EV / Sales: 2.4x
Margin (EBITDA LTM / Revenue): -84.1%
Fundamental value created in LTM:
Market Cap ($m): 1 705
Net Debt ($m): -162
EV (Enterprise Value): 1 543
Price to Book: 186.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-06prnewswire.com

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

2026-02-06businesswire.com

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

2026-02-06prnewswire.com

Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE)

2026-02-06prnewswire.com

RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026

2026-02-06businesswire.com

Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE

2026-02-06prnewswire.com

RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.

2026-02-05businesswire.com

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

2026-02-05businesswire.com

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

2026-02-05globenewswire.com

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

2026-02-04globenewswire.com

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-03
acceptedDate 2025-11-04 18:09:33 2025-08-05 18:21:31 2025-02-19 16:58:50 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33 2022-02-15 16:19:35 2021-02-11 18:37:47
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 160M 166M 560M 139M 147M 109M 434M 98M 108M 100M 363M 91M 351M 271M
costOfRevenue 28M 23M 77M 21M 30M 26M 45M 11M 10M 12M 28M 9M 16M 6M
grossProfit 132M 143M 484M 118M 117M 82M 389M 87M 98M 88M 335M 82M 335M 265M
grossProfitRatio 0.825 0.862 0.849 0.795 0.758 0.888 0.908 0.878 0.905
researchAndDevelopmentExpenses 216M 165M 698M 170M 153M 170M 648M 157M 165M 166M 706M 237M 497M 412M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 87M 87M 322M 80M 81M 78M 310M 75M 81M 77M 278M 70M 220M 183M
otherExpenses 0 0 0 0 -2M -2M 0 5M -2M 7M 0 0 0 0
operatingExpenses 303M 251M 1 019M 250M 233M 248M 958M 232M 246M 242M 984M 307M 717M 595M
costAndExpenses 331M 274M 1 096M 271M 263M 274M 1 003M 243M 256M 255M 1 012M 316M 733M 601M
interestIncome 0 6M 37M 11M 7M 9M 27M 6M 6M 6M 11M 3M 2M 7M
interestExpense 14M 14M 63M 16M 16M 16M 66M 18M 15M 16M 43M 15M 29M 33M
depreciationAndAmortization 9M 9M 36M 9M 9M 9M 26M 5M 5M 7M 18M 2M 13M 12M
ebitda -157M -91M -469M -109M -106M -157M -516M -140M -139M -148M -640M -223M -410M -140M
ebitdaratio -0.98 -0.549 -0.78 -0.731 -1.438 -1.427 -1.28 -1.468 -2.455
operatingIncome -171M -108M -536M -132M -116M -165M -569M -145M -148M -154M -649M -225M -382M -330M
operatingIncomeRatio -1.069 -0.648 -0.946 -0.791 -1.519 -1.48 -1.366 -1.533 -2.481
totalOtherIncomeExpensesNet -9M -6M -32M -1M -14M -5M -39M 4M -2M -9M -53M -14M -71M 145M
incomeBeforeTax -180M -114M -568M -133M -131M -170M -608M -159M -159M -163M -702M -239M -453M -185M
incomeBeforeTaxRatio -1.123 -0.685 -0.955 -0.889 -1.564 -1.622 -1.469 -1.627 -2.633
incomeTaxExpense 873 000 947 000 2M 303 000 858 000 455 000 -2M 650 000 732 000 495 000 6M 6M 1M 1M
netIncome -180M -115M -569M -134M -132M -171M -607M -160M -160M -164M -707M -245M -454M -187M
netIncomeRatio -1.128 -0.69 -0.957 -0.895 -1.568 -1.628 -1.476 -1.632 -2.702
eps -1.808 -1.17 -6.29 -1.4 -1.52 -2.03 -8.25 -2.23 -2.25 -2.33 -10.12 -3.5 -6.7 -3.07
epsdiluted -1.808 -1.17 -1.4 -1.52 -2.03 -2.23 -2.25 -2.33 -3.5
weightedAverageShsOut 100M 98M 91M 95M 87M 84M 74M 72M 71M 70M 70M 70M 68M 61M
weightedAverageShsOutDil 100M 98M 91M 95M 87M 84M 74M 72M 71M 70M 70M 70M 68M 61M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-17 2022-02-15 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -27M -39M -32M -27M -26M
ebit -505M -542M -659M -424M -152M
nonOperatingIncomeExcludingInterest -31M -27M 10M 42M -178M
netIncomeFromContinuingOperations -569M -607M -707M -454M -187M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -569M -607M -707M -454M -187M
epsDiluted -6.29 -8.25 -10.12 -6.7 -3.07

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-03
acceptedDate 2025-11-04 18:09:33 2025-08-05 18:21:31 2025-02-19 16:58:50 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33 2022-02-15 16:19:35 2021-02-11 18:37:47
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 203M 166M 174M 151M 487M 119M 214M 73M 102M 86M 133M 392M 308M 714M
shortTermInvestments 223M 311M 436M 471M 283M 300M 364M 370M 450M 544M 615M 497M 433M 488M
cashAndShortTermInvestments 425M 477M 610M 622M 770M 418M 577M 524M 552M 715M 748M 996M 740M 1 202M
netReceivables 113M 124M 122M 93M 106M 100M 73M 79M 71M 43M 40M 31M 28M 23M
inventory 52M 46M 45M 43M 40M 36M 34M 32M 28M 27M 27M 22M 16M 13M
otherCurrentAssets 53M 71M 40M 41M 55M 41M 48M 46M 51M 67M 69M 71M 0 0
totalCurrentAssets 643M 720M 817M 800M 965M 596M 732M 524M 702M 766M 884M 1 013M 857M 1 295M
propertyPlantEquipmentNet 250M 256M 266M 272M 279M 285M 291M 323M 308M 301M 260M 263M 176M 114M
goodwill 44M 44M 44M 44M 44M 44M 44M 44M 44M 44M 44M 44M 44M 44M
intangibleAssets 173M 175M 178M 165M 166M 165M 166M 157M 158M 159M 160M 158M 131M 131M
goodwillAndIntangibleAssets 217M 219M 223M 209M 211M 209M 211M 202M 203M 204M 205M 203M 175M 176M
longTermInvestments 22M 51M 135M 203M 114M 160M 200M 4M 72M 90M 149M 121M 294M 166M
taxAssets 0 0 0 0 -1 0 0 75M 0 0 0 0 0 0
otherNonCurrentAssets 58M 60M 63M 54M 50M 56M 58M 110M 26M 22M 48M 18M 21M 9M
totalNonCurrentAssets 547M 586M 686M 739M 654M 711M 759M 714M 609M 617M 662M 606M 666M 464M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 1 190M 1 306M 1 503M 1 538M 1 618M 1 307M 1 491M 1 238M 1 311M 1 383M 1 545M 1 618M 1 522M 1 760M
accountPayables 41M 34M 39M 36M 60M 41M 42M 33M 42M 59M 43M 24M 17M 13M
shortTermDebt 78M 12M 0 10M 59M 55M 0 12M 11M 11M 0 12M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 168M 0 1M 3M 8M 59M
otherCurrentLiabilities 222M 247M 87M 239M 154M 149M 143M 209M 24M 148M 0 189M 0 0
totalCurrentLiabilities 340M 293M 344M 285M 273M 246M 280M 254M 244M 218M 261M 227M 181M 190M
longTermDebt 785M 25M 0 24M 868M 849M 0 35M 15M 17M 0 23M 0 0
deferredRevenueNonCurrent 0 0 0 0 26M 28M 0 -35M 881M 0 0 0 1M 7M
deferredTaxLiabilitiesNonCurrent 0 30M 30M 30M 30M 30M 0 32M 32M 32M 32M 33M 33M 33M
otherNonCurrentLiabilities 49M 800M 837M 846M 15M 14M 905M 921M 10M 896M 880M 884M 353M 336M
totalNonCurrentLiabilities 834M 855M 897M 900M 913M 921M 935M 952M 938M 945M 932M 922M 418M 416M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 34M 36M 40M 24M 37M 28M 43M 12M 26M 29M 32M 35M 42M 48M
totalLiabilities 1 174M 1 148M 1 241M 1 185M 1 186M 1 167M 1 216M 1 206M 1 182M 1 163M 1 193M 1 150M 600M 605M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 96 000 96 000 92 000 92 000 92 000 83 000 82 000 72 000 71 000 71 000 70 000 70 000 69 000 67 000
retainedEarnings -4 403M -4 223M -3 957M -3 823M -3 690M -3 558M -3 388M -3 264M -3 105M -2 945M -2 781M -2 629M -2 074M -1 620M
accumulatedOtherComprehensiveIncomeLoss 9M -268 000 -643 000 896 000 2M 3M 647 000 -2M -3M -4M -7M -10M -1M 689 000
othertotalStockholdersEquity 4 404M 4 374M 4 169M 4 120M 3 696M 3 298M 3 237M 3 169M 3 108M
totalStockholdersEquity 9M 151M 255M 347M 432M 140M 275M 32M 129M 220M 352M 469M 923M 1 154M
totalEquity 16M 158M 262M 354M 432M 140M 275M 32M 129M 220M 352M 469M 923M 1 154M
totalLiabilitiesAndStockholdersEquity 1 190M 1 306M 1 538M 1 618M 1 307M 1 238M 1 311M 1 383M 1 618M
minorityInterest 7M 7M 7M 7M 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 190M 1 306M 1 503M 1 538M 1 618M 1 307M 1 491M 1 238M 1 311M 1 383M 1 545M 1 618M 1 522M 1 760M
totalInvestments 245M 363M 571M 674M 397M 460M 564M 374M 455M 549M 764M 618M 726M 654M
totalDebt 863M 36M 40M 34M 927M 932M 43M 12M 26M 29M 32M 35M 42M 48M
netDebt 661M -130M -133M -117M 440M 814M -170M -61M -76M -57M -101M -357M -266M -665M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-17 2022-02-15 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 122M 73M 40M 28M 23M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 72M 58M
totalPayables 39M 42M 43M 17M 13M
otherPayables 0 0 0 0 0
accruedExpenses 208M 83M 205M 146M 108M
capitalLeaseObligationsCurrent 10M 13M 12M 11M 9M
capitalLeaseObligationsNonCurrent 30M 31M 20M 31M 39M
treasuryStock -4M -432 000 0 0 0
additionalPaidInCapital 4 213M 3 662M 3 140M 2 997M 2 773M
otherTotalStockholdersEquity 4M 432 000 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE RARE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-03
acceptedDate 2025-11-04 18:09:33 2025-08-05 18:21:31 2025-02-19 16:58:50 2024-11-05 18:16:09 2024-08-01 18:08:24 2024-05-02 18:05:13 2024-02-21 16:01:34 2023-11-02 18:15:10 2023-08-03 18:03:43 2023-05-04 18:06:50 2023-02-16 18:06:22 2022-11-02 18:06:33 2022-02-15 16:19:35 2021-02-11 18:37:47
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -180M -115M -569M -134M -132M -171M -607M -160M -160M -164M -707M -245M -454M -187M
depreciationAndAmortization 9M -12M 36M -28M 9M 9M 26M 7M 5M 5M 18M 5M 13M 12M
deferredIncomeTax 0 0 0 0 0 0 -2M -1M -3M 0 0 0 49M -170M
stockBasedCompensation 37M 39M 158M 42M 39M 37M 135M 35M 35M 32M 130M 36M 105M 86M
changeInWorkingCapital 10M -22M 14M 31M 16M -56M -15M 3M 7M -38M 60M 22M -63M 105M
accountsReceivables 5M -13M -34M 10M 2M -25M -23M -6M -15M -3M -12M 6M -5M 10M
inventory -6M 208 000 -11M -3M -4M -2M -7M -3M -2M 150 000 -10M -791 000 -3M -1M
accountsPayables 0 -10M 47M 11M 25M -36M 2M 7M 0 -34M 80M 11M 3M 30M
otherWorkingCapital 10M 313 000 12M 13M -7M 7M 12M 5M 24M -2M 2M 6M -57M 67M
otherNonCashItems 34M 2M -52M 22M 24M 107M -13M -2M -27 000 8M 118M 87M 12M 21M
netCashProvidedByOperatingActivities -91M -108M -414M -67M -77M -191M -475M -118M -116M -157M -380M -95M -339M -132M
investmentsInPropertyPlantAndEquipment -1M -2M -7M -2M -5M -13M -44M -4M -16M -25M -116M -26M -73M -44M
acquisitionsNet 0 0 0 0 0 0 0 0 -3M 0 -75M 0 0 0
purchasesOfInvestments 0 -16M -409M -367M -3M -22M -526M -139M -103M -62M -615M -211M -1 012M -850M
salesMaturitiesOfInvestments 0 89M 413M 94M 68M 132M 746M 208M 220M 202M 545M 151M 891M 721M
otherInvestingActivites 118M -308 000 -203 000 -41 000 -2M -428 000 2M -4M -76M
netCashUsedForInvestingActivites 117M 71M -276M 61M 94M 64M 99M 111M -162M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 84M 117 000 385M -58 000 25M 0 -750 000 0
commonStockRepurchased 0 0 0 0 58 000 -58 000 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2000 0 11M 385M -58 000 442 000 33M 28 000 492M
netCashUsedProvidedByFinancingActivities 2000 84M 11M 385M -58 000 25M 33M -722 000 492M
effectOfForexChangesOnCash 294 000 3M -3M 1M -648 000 -679 000 462 000 -716 000 -136 000 211 000 -1M -1M -1M 1M
netChangeInCash 26M 49M -35M -327M 368M -97M 82M -29M 16M -46M -172M 234M -417M 290M
cashAtEndOfPeriod 215M 189M 184M 160M 487M 119M 219M 79M 108M 92M 138M 396M 310M 726M
cashAtBeginningOfPeriod 189M 139M 219M 487M 119M 216M 138M 108M 92M 138M 310M 163M 726M 436M
operatingCashFlow -91M -108M -414M -67M -77M -191M -475M -118M -116M -157M -380M -95M -339M -132M
capitalExpenditure -1M 13M -7M -2M -5M -13M -47M -4M -16M -25M -146M -26M -73M -44M
freeCashFlow -93M -96M -422M -69M -81M -204M -522M -122M -133M -182M -527M -121M -412M -176M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-21 2023-02-17 2022-02-15 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -15M -8M -31M -942 000 -6M
netCashProvidedByInvestingActivities -18M 168M -292M -195M -179M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 381M 380M 0 79M 511M
netCommonStockIssuance 381M 380M 0 79M 511M
commonStockIssuance 381M 380M 0 79M 511M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 18M 8M 501M 40M 89M
netCashProvidedByFinancingActivities 399M 388M 501M 119M 600M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-02 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-07-29 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-04 23:09 ET
Ultragenyx Pharmaceutical reported for 2025 q3
SEC form 10
2025-08-05 22:21 ET
Ultragenyx Pharmaceutical reported for 2025 q2
SEC form 8
2025-08-05 20:07 ET
Ultragenyx Pharmaceutical published news for 2025 q2
SEC form 8
2025-08-05 20:07 ET
Ultragenyx Pharmaceutical published news for 2025 q2
SEC form 10
2025-05-07 00:00 ET
Ultragenyx Pharmaceutical published news for 2025 q1
SEC form 10
2025-05-06 22:09 ET
Ultragenyx Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-06 20:10 ET
Ultragenyx Pharmaceutical published news for 2025 q1
SEC form 8
2025-05-06 20:10 ET
Ultragenyx Pharmaceutical reported for 2025 q1
SEC form 10
2025-02-19 21:58 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 10
2025-02-19 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
Ultragenyx Pharmaceutical reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q4
SEC form 10
2024-11-05 18:16 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 8
2024-11-05 16:06 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 8
2024-11-05 16:06 ET
Ultragenyx Pharmaceutical published news for 2024 q3
SEC form 10
2024-08-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 10
2024-08-01 18:08 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 8
2024-08-01 16:07 ET
Ultragenyx Pharmaceutical published news for 2024 q2
SEC form 8
2024-08-01 16:07 ET
Ultragenyx Pharmaceutical reported for 2024 q2
SEC form 10
2024-05-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 10
2024-05-02 18:05 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 8
2024-05-02 16:02 ET
Ultragenyx Pharmaceutical published news for 2024 q1
SEC form 8
2024-05-02 16:02 ET
Ultragenyx Pharmaceutical reported for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Ultragenyx Pharmaceutical reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 10
2023-11-02 18:15 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 8
2023-11-02 16:17 ET
Ultragenyx Pharmaceutical reported for 2023 q3
SEC form 8
2023-10-16 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 10
2023-08-03 18:03 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-08-03 16:08 ET
Ultragenyx Pharmaceutical reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-12 08:15 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-06 08:15 ET
Ultragenyx Pharmaceutical published news for 2023 q2
SEC form 6
2023-06-13 13:00 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-05 16:17 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Ultragenyx Pharmaceutical published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Ultragenyx Pharmaceutical reported for 2023 q1
SEC form 6
2023-03-23 17:00 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-14 08:35 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 10
2023-02-17 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 10
2023-02-16 18:06 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 6
2023-02-16 16:08 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q4
SEC form 6
2023-01-06 16:19 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Ultragenyx Pharmaceutical published news for 2022 q4
SEC form 6
2022-11-10 16:26 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 10
2022-11-02 18:06 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q3
SEC form 6
2022-10-28 16:10 ET
Ultragenyx Pharmaceutical published news for 2022 q3
SEC form 6
2022-09-15 16:07 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 10
2022-07-29 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 10
2022-07-28 18:17 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 6
2022-07-28 16:09 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q2
SEC form 6
2022-07-18 16:12 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-14 08:36 ET
Ultragenyx Pharmaceutical published news for 2022 q2
SEC form 6
2022-06-27 16:12 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-17 08:06 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 10
2022-05-05 18:13 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 6
2022-05-05 16:01 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Ultragenyx Pharmaceutical reported for 2022 q1
SEC form 6
2022-04-28 16:10 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-22 12:30 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-22 08:05 ET
Ultragenyx Pharmaceutical published news for 2022 q1
SEC form 10
2022-02-15 16:19 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 10
2022-02-15 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-10 16:11 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-10 08:24 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-07 07:16 ET
Ultragenyx Pharmaceutical published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 10
2021-11-02 18:20 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-02 16:14 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-07 08:18 ET
Ultragenyx Pharmaceutical published news for 2021 q3
SEC form 6
2021-09-27 08:16 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 10
2021-08-02 18:36 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-02 16:10 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 8
2021-08-02 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q2
SEC form 6
2021-06-30 19:56 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-30 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-25 09:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-10 08:35 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-19 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-14 08:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-07 16:46 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-05-04 18:32 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-04 16:06 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-29 16:01 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-16 06:03 ET
Ultragenyx Pharmaceutical published news for 2021 q1
SEC form 10
2021-02-11 18:37 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-11 16:07 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-21 08:46 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-11 07:15 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-08 09:16 ET
Ultragenyx Pharmaceutical published news for 2020 q4
SEC form 6
2020-12-17 16:15 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-12-07 06:04 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-02 16:05 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 10
2020-10-27 16:20 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-27 16:07 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-26 16:11 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-23 08:16 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-13 17:52 ET
Ultragenyx Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-13 06:07 ET
Ultragenyx Pharmaceutical published news for 2020 q3